【US Stock Movements】Grail surged on October 9: Regulatory support, Galleri data, and growth in testing

Grail October 9th Surge Interpretation

Keywords: Regulatory Support, Galleri Data, Detection Growth

1. On September 23rd, the FDA Medical Devices Advisory Committee voted 10 to 0 on the safety of Galleri, 7 to 2 that the benefits outweigh the risks, and 6 to 4 on its effectiveness, providing regulatory progress for subsequent PMA review.

2. From October 6th to 8th, GRAIL presented six sets of data at EDCC regarding Galleri's clinical performance, health equity, and real-world applications, including detection of more than 200 types of cancer and determination of cancer signal sources.

3. As of June 30th, Galleri's testing volume in the first half of the year increased by 42% year-on-year to over 117,000 tests; the company mainly focuses on early detection of multiple cancer types, with Galleri as a commercialized blood screening product.

(Disclaimer: This content is summarized from publicly available information using AI technology and is for reference only. It does not constitute investment advice.)